CYTK - Cytokinetics Inc Stock Price, Fair Value and News

$51.01+0.37 (+0.73%)

Delayed as of 03 Dec 2024, 12:00 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CYTK Price Action

Last 7 days

0.8%

Last 30 days

-2.3%

Last 90 days

-7.2%

Trailing 12 Months

50.8%

CYTK RSI Chart

CYTK Valuation

Market Cap

6.0B

Price/Earnings (Trailing)

-10.37

Price/Sales (Trailing)

1.9K

EV/EBITDA

209.12

Price/Free Cashflow

-14.68

CYTK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CYTK Fundamentals

CYTK Revenue

Revenue (TTM)

3.2M

Rev. Growth (Yr)

22.49%

Rev. Growth (Qtr)

85.94%

CYTK Earnings

Earnings (TTM)

-576.4M

Earnings Growth (Yr)

-24.05%

Earnings Growth (Qtr)

-12.02%

CYTK Profitability

EBT Margin

-550.02%

Return on Equity

4.1K%

Return on Assets

-40.14%

Free Cashflow Yield

-6.81%

CYTK Investor Care

Shares Dilution (1Y)

20.36%

Diluted EPS (TTM)

-5.38

CYTK Alerts

3 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.8M	3.1M	3.2M	0
2023	98.1M	10.0M	7.8M	7.5M
2022	76.5M	82.5M	88.5M	94.6M
2021	58.6M	57.8M	21.6M	70.4M
2020	22.2M	18.7M	54.3M	55.8M
2019	34.7M	35.6M	31.0M	26.9M
2018	17.9M	22.4M	27.0M	31.5M
2017	102.1M	99.4M	46.5M	13.4M
2016	32.7M	31.9M	83.0M	106.4M
2015	43.4M	42.1M	40.7M	28.7M
2014	37.8M	44.6M	49.5M	46.9M
2013	6.6M	5.7M	8.5M	30.6M
2012	5.1M	5.8M	6.1M	7.6M
2011	2.9M	3.3M	4.3M	4.0M
2010	0	55.2M	28.9M	2.6M
2009	0	0	0	81.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CEO	Mr. Robert I. Blum
WEBSITE	cytokinetics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	409

Cytokinetics Inc Frequently Asked Questions

What is the ticker symbol for Cytokinetics Inc? What does CYTK stand for in stocks?

CYTK is the stock ticker symbol of Cytokinetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cytokinetics Inc (CYTK)?

As of Mon Dec 02 2024, market cap of Cytokinetics Inc is 5.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYTK stock?

You can check CYTK's fair value in chart for subscribers.

Is Cytokinetics Inc a good stock to buy?

The fair value guage provides a quick view whether CYTK is over valued or under valued. Whether Cytokinetics Inc is cheap or expensive depends on the assumptions which impact Cytokinetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYTK.

What is Cytokinetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 02 2024, CYTK's PE ratio (Price to Earnings) is -10.37 and Price to Sales (PS) ratio is 1.86 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYTK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cytokinetics Inc's stock?

In the past 10 years, Cytokinetics Inc has provided 0.269 (multiply by 100 for percentage) rate of return.